Poullenot et al. [30] analyzed the risk of incident new or recurrent cancer in a multicenter cohort of 79 IBD patients with a recent history of cancer (median time 17 months, range 1–65; mainly breast and skin cancers) who were subsequently treated with at least one anti-TNFα (53 IFX, 26 ADA). The gene discussed is TNF; the disease is inflammatory bowel disease.